Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Balance Sheet
Balance Sheet Decomposition
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc
Balance Sheet
Amylyx Pharmaceuticals Inc
| Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Cash Equivalents |
3
|
13
|
50
|
63
|
170
|
77
|
|
| Cash Equivalents |
3
|
13
|
50
|
63
|
170
|
77
|
|
| Short-Term Investments |
0
|
0
|
46
|
284
|
201
|
99
|
|
| Total Receivables |
0
|
0
|
0
|
15
|
40
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
15
|
40
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
10
|
38
|
0
|
|
| Other Current Assets |
0
|
1
|
9
|
10
|
15
|
12
|
|
| Total Current Assets |
3
|
14
|
105
|
382
|
465
|
189
|
|
| PP&E Net |
0
|
0
|
0
|
8
|
6
|
3
|
|
| PP&E Gross |
0
|
0
|
0
|
8
|
6
|
3
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
1
|
2
|
1
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
1
|
46
|
1
|
|
| Total Assets |
3
N/A
|
14
+338%
|
106
+649%
|
391
+271%
|
517
+32%
|
194
-63%
|
|
| Liabilities | |||||||
| Accounts Payable |
2
|
4
|
4
|
6
|
22
|
3
|
|
| Accrued Liabilities |
2
|
4
|
13
|
40
|
60
|
25
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
5
|
7
|
17
|
47
|
82
|
28
|
|
| Long-Term Debt |
15
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
1
|
1
|
0
|
4
|
2
|
0
|
|
| Total Liabilities |
21
N/A
|
9
-58%
|
17
+99%
|
51
+192%
|
84
+65%
|
29
-66%
|
|
| Equity | |||||||
| Common Stock |
8
|
72
|
239
|
0
|
0
|
0
|
|
| Retained Earnings |
26
|
68
|
156
|
354
|
305
|
607
|
|
| Additional Paid In Capital |
0
|
1
|
5
|
695
|
738
|
772
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
18
N/A
|
5
N/A
|
88
+1 552%
|
341
+286%
|
433
+27%
|
165
-62%
|
|
| Total Liabilities & Equity |
3
N/A
|
14
+338%
|
106
+649%
|
391
+271%
|
517
+32%
|
194
-63%
|
|
| Shares Outstanding | |||||||
| Common Shares Outstanding |
56
|
56
|
56
|
67
|
68
|
69
|
|
| Preferred Shares Outstanding |
0
|
0
|
37
|
0
|
0
|
0
|
|